PT - JOURNAL ARTICLE AU - Gil, Saulo AU - Filho, Wilson Jacob AU - Shinjo, Samuel Katsuyuki AU - Ferriolli, Eduardo AU - Busse, Alexandre Leopold AU - Avelino-Silva, Thiago Junqueira AU - Longobardi, Igor AU - de Oliveira, Gersiel Nascimento AU - Swinton, Paul AU - Gualano, Bruno AU - Roschel, Hamilton AU - , AU - Bonfá, Eloisa AU - Utiyama, Edivaldo AU - Segurado, Aluisio AU - Perondi, Beatriz AU - Morais, Anna Miethke AU - Montal, Amanda AU - Letaif, Leila AU - Fusco, Solange AU - da Silva, Marjorie Fregonesi Rodrigues AU - Rocha, Marcelo AU - Marcilio, Izabel AU - Rios, Izabel Cristina AU - Kawano, Fabiane Yumi Ogihara AU - Amélia de Jesus, Maria AU - Kallas, Ésper Georges AU - Carmo, Carolina AU - Tanaka, Clarice AU - de Souza, Heraldo Possolo AU - Marchini, Julio F. M. AU - Carvalho, Carlos AU - Ferreira, Juliana Carvalho AU - Levin, Anna Sara Shafferman AU - de Oliveira, Maura Salaroli AU - Guimarães, Thaís AU - Lázari, Carolina dos Santos AU - José da Silva Duarte, Alberto AU - Sabino, Ester AU - Magri, Marcello Mihailenko Chaves AU - Barros-Filho, Tarcisio E. P. AU - Francisco, Maria Cristina Peres Braido TI - Muscle Strength and Muscle Mass as Predictors of Hospital Length of Stay in Patients with Moderate to Severe COVID-19: A Prospective Observational Study AID - 10.1101/2021.03.30.21254578 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.30.21254578 4099 - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254578.short 4100 - http://medrxiv.org/content/early/2021/03/31/2021.03.30.21254578.full AB - Importance Strength and muscle mass are predictors of relevant clinical outcomes in critically ill patients, but in hospitalized patients with COVID-19 remains to be determined.Objective To investigate whether muscle strength or muscle mass are predictive of hospital length of stay (LOS) in patients with moderate to severe COVID-19.Design Prospective observational study.Setting Clinical Hospital of the School of Medicine of the University of Sao Paulo.Participants One hundred ninety-six patients were evaluated. Ten patients did not test positive for SARS-CoV-2 during hospitalization and were excluded from the analyses. The sample comprised patients of both sexes (50% male) with a mean age (SD) of 59 (±15) years, body mass index of 29.5 (±6.9) kg/m2. The prevalence of current smoking patients was 24.7%, and more prevalent coexisting conditions were hypertension (67.7%), obesity (40.9%), and type 2 diabetes (36.0%). Mean (SD) LOS was 8.6 days (7.7); 17.0% of the patients required intensive care; 3.8% used invasive mechanical ventilation; and 6.6% died during the hospitalization period.Main outcome The outcome was LOS, defined as time from hospital admission to medical discharge.Results The crude Hazard Ratio (HR) for LOS was greatest for handgrip strength comparing the strongest vs. other patients (1.54 [95%CI: 1.12 – 2.12; p = 0.008]). Evidence of an association between increased handgrip strength and shorter hospital stay was also identified when handgrip strength was standardized according to the sex-specific mean and standard deviation (1.23 [95%CI: 1.06 – 1.19; p = 0.008]). The magnitude of these associations remained consistent and statistically significant after adjusting for other covariates. Mean LOS was shorter for the strongest patients (7.5 ± 6.1 days) vs. others (9.2 ± 8.4 days). Evidence of associations were also present for vastus lateralis cross-sectional area. The crude HR identified shorter hospital stay for patients with greater sex-specific standardized values (1.17 [95%CI: 1.01 – 1.36; p = 0.037]); however, we found increased uncertainty in the estimate with the addition of other covariates (1.18 [95%CI: 0.97 – 1.43; p = 0.092]). Evidence was also obtained associating longer hospital stays for patients with the lowest values for vastus lateralis cross-sectional area (0.69 [95%CI: 0.50 – 0.95; p = 0.025). Mean LOS for the patients with the lowest muscle cross-sectional area was longer (10.8 ± 8.8 days) vs. others (7.7 ± 7.2 days).Conclusions and Relevance Muscle strength and mass assessed upon hospital admission are predictors of LOS in patients with moderate to severe COVID-19, which stresses the value of muscle health in prognosis of this disease.Funding The authors acknowledge the support by the Brazilian National Council for Scientific and Technological Development (CNPq - grant 301571/2017-1). H.R. and B.G. are supported by grants from the Conselho Nacional de Pesquisa e Desenvolvimento (CNPq 428242/2018-9; 301571/2017-1; 301914/2017-6). B.G. is also supported by a grant from the Sao Paulo Research Foundation (FAPESP 2017/13552-2).Question Do muscle strength and muscle mass predict hospital length of stay (LOS) in patients with moderate to severe COVID-19 patients?Findings In this prospective observational study that included 186 hospitalized patients with moderate to severe COVID-19, we observed that LOS was shorter among patients in the highest tertile of strength (assessed by handgrip) vs. those in the mid/lowest tertiles (crude Hazard Ratio [HR]: 1.54, 95%CI: 1.12-2.12). In addition, LOS was longer among patients in the lowest tertile of muscle cross-sectional area (assessed by ultrasound imaging) vs. those in the mid/highest tertiles (HR: 0.69, 95%CI: 0.50 – 0.95).Meaning Muscle strength and mass assessed on hospital admission are predictors of LOS in patients with moderate to severe COVID-19, suggesting that muscle health may be protective in this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Clinical Hospital of the School of Medicine of the University of Sao Paulo in Brazil (HCFMUSP) (Ethics Committee Approval Number: 31303720.7.0000.0068).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther information and requests for database should be directed to and will be fulfilled by the Lead Contact, Hamilton Roschel (hars{at}usp.br).